Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming
Cancer drugs conjugated with toxins are evolving beyond breast cancer's HER2 target toward immunotherapy combinations with wider reach.
This review synthesizes the evolving ADC landscape in breast cancer, covering target expansion beyond HER2 to TROP-2/HER3, improved linker designs, resistance mechanisms, and emerging ADC+immunotherapy combinations. It provides a useful framework for understanding how ADCs are transitioning from precision cytotoxics to immunomodulatory agents.
What the study was
- Study design
- Narrative review
- Population
- Breast cancer patients (HER2+, TNBC, HER3+)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal of Hematology & Oncology
Why it surfaced
Current state-of-the-art ADC review in J Hematol Oncol; useful pipeline context for breast cancer treatment landscape.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.